聚乙二醇修饰的羟基喜树碱纳米脂质载体的制备及其小鼠组织分布

被引:43
作者
张馨欣 [1 ]
甘勇 [2 ]
杨星钢 [1 ]
朱春柳 [2 ]
甘莉 [2 ]
聂淑芳 [1 ]
潘卫三 [1 ]
机构
[1] 沈阳药科大学药学院
[2] 中国科学院上海药物研究所
关键词
羟基喜树碱; 纳米脂质载体; 组织分布; 肺靶向性;
D O I
暂无
中图分类号
R94 [药剂学]; R96 [药理学];
学科分类号
100702 [药剂学]; 100706 [药理学];
摘要
本研究采用熔融乳化-高压均质法制备了聚乙二醇(PEG)修饰的羟基喜树碱(HCPT)纳米脂质载体(HCPT-PEG-NLC)及非修饰的羟基喜树碱纳米脂质载体(HCPT-NLC),并考察了其形态、粒径及包封率。测定了HCPT注射液、HCPT-PEG-NLC及HCPT-NLC 3种制剂经小鼠尾静脉注射后在血浆、心、肝、脾、肺、肾及卵巢等主要组织的浓度,评价了HCPT-PEG-NLC及HCPT-NLC在各组织的靶向性效果。透射电镜下观察,HCPT-PEG-NLC及HCPT-NLC呈球形;测得平均粒径分别为(88.6±22.5)和(127.2±43.4)nm;包封率分别为(90.51±3.29)%和(84.37±2.81)%。经小鼠尾静脉注射后,HCPT-PEG-NLC及HCPT-NLC在多数取样时间点的血药浓度较HCPT注射液有所提高,HCPT在各组织中的消除半衰期明显延长。HCPT-NLC蓄集于网状内皮系统(RES),在肝、脾的相对摄取率(Re)和峰浓度比(Ce)明显高于HCPT-PEG-NLC。HCPT-PEG-NLC延长了药物在血浆中的滞留时间,提高了生物利用度,MRT及AUC0-24 h分别为注射液的19.80和17.02倍,并且与HCPT-NLC比较显著降低了RES的吞噬作用,在肺部表现出明显的靶向作用(Re及Ce分别为14.51,41.35)。综上,HCPT-PEG-NLC可延长HCPT的体内循环时间,呈现明显的肺靶向性,有望作为HCPT肺癌治疗的理想载体。
引用
收藏
页码:91 / 96
页数:6
相关论文
共 6 条
[1]
Preparation and antitumor characteristics of PLA/(PEG-PPG-PEG) nanoparticles loaded with camptothecin[J] Ryotaro Kunii;Hiraku Onishi;Yoshiharu Machida European Journal of Pharmaceutics and Biopharmaceutics 2007,
[2]
Protein–lipid interactions and surface activity in the pulmonary surfactant system[J] Alicia G. Serrano;Jesús Pérez-Gil Chemistry and Physics of Lipids 2006,
[3]
Development of a controlled release formulation based on SLN and NLC for topical clotrimazole delivery[J] E.B Souto;S.A Wissing;C.M Barbosa;R.H Müller International Journal of Pharmaceutics 2004,
[4]
Nanostructured lipid matrices for improved microencapsulation of drugs[J] R.H Müller;M Radtke;S.A Wissing International Journal of Pharmaceutics 2002,
[5]
Effects of mixed polyethyleneglycol modification on fixed aqueous layer thickness and antitumor activity of doxorubicin containing liposome[J] Yasuyuki Sadzuka;Akiko Nakade;Rieko Hirama;Atsuo Miyagishima;Yasuo Nozawa;Sadao Hirota;Takashi Sonobe International Journal of Pharmaceutics 2002,
[6]
Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations[J] R.H. Müller;M. Radtke;S.A. Wissing Advanced Drug Delivery Reviews 2002,